Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a buy rating to a strong-buy rating in a research report released on Sunday,Wall Street Zen reports.

A number of other research firms have also issued reports on REGN. Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a “hold” rating in a research note on Wednesday, July 29th. Royal Bank Of Canada upped their target price on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. Piper Sandler dropped their price target on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a research note on Thursday, July 9th. Benchmark raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a research note on Tuesday, July 7th. Finally, Guggenheim boosted their price objective on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Fourteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $802.18.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $803.90 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. Regeneron Pharmaceuticals has a 1-year low of $541.00 and a 1-year high of $859.34. The company has a market capitalization of $82.77 billion, a price-to-earnings ratio of 19.87, a PEG ratio of 1.56 and a beta of 0.20. The business has a 50-day moving average of $772.49 and a 200-day moving average of $720.57.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company’s revenue was up 16.7% on a year-over-year basis. During the same period last year, the business posted $12.81 EPS. On average, equities analysts anticipate that Regeneron Pharmaceuticals will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals’s payout ratio is 9.29%.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Zoghbi sold 800 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. This trade represents a 31.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the completion of the sale, the director directly owned 603 shares of the company’s stock, valued at $512,550. The trade was a 39.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 4,146 shares of company stock valued at $3,432,488. Insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of REGN. Andra AP fonden grew its position in shares of Regeneron Pharmaceuticals by 583.2% in the 2nd quarter. Andra AP fonden now owns 28,912 shares of the biopharmaceutical company’s stock worth $18,028,000 after acquiring an additional 24,680 shares in the last quarter. State Street Corp raised its position in shares of Regeneron Pharmaceuticals by 3.6% during the 2nd quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock valued at $3,014,621,000 after acquiring an additional 170,210 shares in the last quarter. Tidal Investments LLC lifted its stake in Regeneron Pharmaceuticals by 10.7% during the second quarter. Tidal Investments LLC now owns 43,896 shares of the biopharmaceutical company’s stock worth $27,371,000 after purchasing an additional 4,244 shares during the last quarter. National Pension Service lifted its stake in Regeneron Pharmaceuticals by 2.2% during the second quarter. National Pension Service now owns 379,815 shares of the biopharmaceutical company’s stock worth $236,830,000 after purchasing an additional 8,264 shares during the last quarter. Finally, Krensavage Asset Management LLC boosted its holdings in Regeneron Pharmaceuticals by 50.0% in the second quarter. Krensavage Asset Management LLC now owns 6,000 shares of the biopharmaceutical company’s stock worth $3,741,000 after purchasing an additional 2,000 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron’s marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.